{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:27:57Z","timestamp":1781184477499,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is an unmet need for rapid, accurate, and noninvasive assays for diagnosis and monitoring of Mycobacterium avium complex pulmonary disease (MAC-PD). We evaluated the diagnostic accuracy of an anti-glycopeptidolipid (GPL)-core immunoglobulin A (IgA) antibody test in a US cohort of MAC patients, and we described serial serology changes during antimicrobial therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified serum samples from MAC patients starting treatment at enrollment and control subjects with or without bronchiectasis within OHSU's NTM Biobank. We conducted diagnostic test accuracy. Changes in mean levels of anti-GPL-core IgA antibodies between 0 and 3, 6, or 12 months after treatment start were assessed using the Student's paired t test. Pearson's correlation coefficient was calculated for IgA antibody levels and Student paired t test measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 25 MAC patients and 18 controls. At baseline, IgA antibody concentrations in MAC patients (3.40 \u00b1 6.77\u2005U\/mL) were significantly higher than in controls without bronchiectasis (0.14 \u00b1 0.03\u2005U\/mL, P = .02). Sensitivity and specificity for MAC-PD in this population was 48% and 89% (cutoff point 0.7\u2005U\/mL), respectively. Among MAC patients starting antimicrobial therapy, mean IgA levels decreased 0.3202\u2005U\/mL (P = .86) at month 3, 0.8678\u2005U\/mL (P = .47) at month 6, and 1.9816\u2005U\/mL (P = .41) at 1 year. Quality of Life-Bronchiectasis Respiratory Symptom Scale improvement correlated with decreasing IgA titers after 12 months of treatment in MAC patients (r = \u22120.50, P = .06).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anti-GPL-core IgA antibody levels are relatively specific for MAC-PD and decrease with treatment. Larger studies are warranted to evaluate the role of IgA serology in monitoring treatment response or for disease relapse\/reinfection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac528","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T04:57:44Z","timestamp":1666414664000},"source":"Crossref","is-referenced-by-count":10,"title":["Use of Anti-Glycopeptidolipid-Core Antibodies Serology for Diagnosis and Monitoring of <i>Mycobacterium avium<\/i> Complex Pulmonary Disease in the United States"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-4695","authenticated-orcid":false,"given":"A G","family":"Hernandez","sequence":"first","affiliation":[{"name":"Center for Infectious Disease Studies, School of Public Health, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Brunton","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Studies, School of Public Health, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ato","sequence":"additional","affiliation":[{"name":"Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases , Aoba-cho, Higashimurayama, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association , Matsuyama, Kiyose City, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases , Aoba-cho, Higashimurayama, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Henkle","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Studies, School of Public Health, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Studies, School of Public Health, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"2022110513190336800_ofac528-B1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0033-1333567","article-title":"Update on the epidemiology of pulmonary nontuberculous mycobacterial infections","volume":"34","author":"Kendall","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"2022110513190336800_ofac528-B2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2022110513190336800_ofac528-B3","doi-asserted-by":"crossref","first-page":"e124\u20139","DOI":"10.1086\/648443","article-title":"Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology","volume":"49","author":"Cassidy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022110513190336800_ofac528-B4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2022110513190336800_ofac528-B5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2022110513190336800_ofac528-B6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7883\/yoken.67.329","article-title":"Serodiagnosis of Mycobacterium avium complex disease in humans: translational research from basic mycobacteriology to clinical medicine","volume":"67","author":"Kobayashi","year":"2014","journal-title":"Jpn J Infect Dis"},{"key":"2022110513190336800_ofac528-B7","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1086\/344277","article-title":"Serodiagnosis of pulmonary disease due to Mycobacterium avium complex with an enzyme immunoassay that uses a mixture of glycopeptidolipid antigens","volume":"35","author":"Kitada","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2022110513190336800_ofac528-B8","first-page":"44","article-title":"Use of glycopeptidolipid core antigen for serodiagnosis of Mycobacterium avium complex pulmonary disease in immunocompetent patients","volume":"12","author":"Kitada","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"2022110513190336800_ofac528-B9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1183\/09031936.00061806","article-title":"Serological test and chest computed tomography findings in patients with Mycobacterium avium complex lung disease","volume":"29","author":"Kitada","year":"2007","journal-title":"Eur Respir J"},{"key":"2022110513190336800_ofac528-B10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1164\/rccm.200705-771OC","article-title":"Serodiagnosis of Mycobacterium avium\u2014complex pulmonary disease using an enzyme immunoassay kit","volume":"177","author":"Kitada","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2022110513190336800_ofac528-B11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5588\/ijtld.14.0564","article-title":"Validation of a commercial serodiagnostic kit for diagnosing pulmonary Mycobacterium avium complex disease","volume":"19","author":"Kitada","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2022110513190336800_ofac528-B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365548.2012.714904","article-title":"Serological assay by use of glycopeptidolipid core antigen for Mycobacterium avium complex","volume":"45","author":"Kobashi","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"2022110513190336800_ofac528-B13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000354791","article-title":"Serodiagnosis of Mycobacterium avium complex pulmonary disease in rheumatoid arthritis","volume":"87","author":"Komazaki","year":"2014","journal-title":"Respiration"},{"key":"2022110513190336800_ofac528-B14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/resp.12640","article-title":"Clinical efficacy of anti-glycopeptidolipid-core IgA test for diagnosing Mycobacterium avium complex infection in lung.","volume":"20","author":"Numata","year":"2015","journal-title":"Respirology"},{"key":"2022110513190336800_ofac528-B15","first-page":"399","article-title":"Serum glycopeptidolipid core IgA antibody levels in patients with chest computed tomography features of mycobacterium aviumintracellulare complex pulmonary disease","volume":"28","author":"Shimizu","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"2022110513190336800_ofac528-B16","volume-title":"Statistical methods in diagnostic medicine","author":"Zhou","year":"2014"},{"key":"2022110513190336800_ofac528-B17","volume-title":"Analyzing receiver operating characteristic curves with SAS\u00ae","author":"G\u00f6nen","year":"2007"},{"key":"2022110513190336800_ofac528-B18","volume-title":"\u201cReceiver operating characteristic (ROC) curve for medical researchers\u201d","author":"Kumar","year":"2007"},{"key":"2022110513190336800_ofac528-B19","doi-asserted-by":"crossref","first-page":"1901300","DOI":"10.1183\/13993003.01300-2019","article-title":"Preliminary validation of the NTM module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease","volume":"55","author":"Henkle","year":"2020","journal-title":"Eur Respir J"},{"key":"2022110513190336800_ofac528-B20","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/JCM.00702-13","article-title":"Serodiagnosis of Mycobacterium avium complex and Mycobacterium abscessus complex pulmonary disease by use of IgA antibodies to glycopeptidolipid core antigen","volume":"51","author":"Jeong","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2022110513190336800_ofac528-B21","doi-asserted-by":"crossref","first-page":"e80473","DOI":"10.1371\/journal.pone.0080473","article-title":"Sero-diagnosis of Mycobacterium avium complex lung disease using serum immunoglobulin A antibody against glycopeptidolipid antigen in Taiwan","volume":"8","author":"Shu","year":"2013","journal-title":"PLoS One"},{"key":"2022110513190336800_ofac528-B22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1183\/09031936.00098212","article-title":"Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA","volume":"42","author":"Kitada","year":"2013","journal-title":"Eur Respir J"},{"key":"2022110513190336800_ofac528-B23","doi-asserted-by":"crossref","first-page":"29325","DOI":"10.1038\/srep29325","article-title":"Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis","volume":"6","author":"Shibata","year":"2016","journal-title":"Sci Rep"},{"key":"2022110513190336800_ofac528-B24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/glycob\/cwn076","article-title":"The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis","volume":"18","author":"Schorey","year":"2008","journal-title":"Glycobiology"},{"key":"2022110513190336800_ofac528-B25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"2022110513190336800_ofac528-B26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7883\/yoken.JJID.2016.523","article-title":"Changes in Serum IgA antibody levels against the glycopeptidolipid core antigen during antibiotic treatment of Mycobacterium avium complex lung disease","volume":"70","author":"Jhun","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"2022110513190336800_ofac528-B27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/JCM.02010-16","article-title":"Levels of antibody against glycopeptidolipid core as a marker for monitoring treatment response in Mycobacterium avium complex pulmonary disease: a prospective cohort study","volume":"55","author":"Kitada","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2022110513190336800_ofac528-B28","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1513\/AnnalsATS.201605-387WS","article-title":"Patient-centered research priorities for pulmonary nontuberculous mycobacteria (NTM) infection. An NTM Research Consortium Workshop Report","volume":"13","author":"Henkle","year":"2016","journal-title":"Ann Am Thorac Soc"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac528\/46602157\/ofac528.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/11\/ofac528\/46828841\/ofac528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/11\/ofac528\/46828841\/ofac528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T13:19:40Z","timestamp":1667654380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac528\/6768592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac528","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,10,22]]},"article-number":"ofac528"}}